AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) SVP Julie Krop sold 4,938 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $20.00, for a total transaction of $98,760.00. Following the transaction, the senior vice president now directly owns 28,336 shares of the company’s stock, valued at $566,720. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Julie Krop also recently made the following trade(s):
- On Monday, May 1st, Julie Krop sold 1,891 shares of AMAG Pharmaceuticals stock. The stock was sold at an average price of $24.45, for a total transaction of $46,234.95.
Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) traded up 1.30% during midday trading on Monday, reaching $19.55. The company’s stock had a trading volume of 66,862 shares. AMAG Pharmaceuticals, Inc. has a one year low of $16.00 and a one year high of $36.83. The stock’s market cap is $685.13 million. The firm has a 50-day moving average of $18.21 and a 200-day moving average of $21.64.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by $1.15. The business had revenue of $139.47 million during the quarter, compared to the consensus estimate of $150.32 million. AMAG Pharmaceuticals had a negative net margin of 5.61% and a positive return on equity of 1.69%. The firm’s revenue for the quarter was up 27.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.22) EPS. On average, analysts forecast that AMAG Pharmaceuticals, Inc. will post $5.40 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece was reported by BBNS and is the property of of BBNS. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://baseballnewssource.com/markets/julie-krop-sells-4938-shares-of-amag-pharmaceuticals-inc-amag-stock/1268502.html.
AMAG has been the subject of several research reports. Cantor Fitzgerald reaffirmed a “hold” rating and set a $23.00 price target on shares of AMAG Pharmaceuticals in a research note on Tuesday, May 2nd. TheStreet cut shares of AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a research note on Friday, May 5th. Barclays PLC reaffirmed an “equal weight” rating and set a $20.00 price target (down from $25.00) on shares of AMAG Pharmaceuticals in a research note on Thursday, June 1st. Jefferies Group LLC reaffirmed a “buy” rating and set a $34.00 price target (down from $40.00) on shares of AMAG Pharmaceuticals in a research note on Wednesday, May 3rd. Finally, ValuEngine cut shares of AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $28.09.
A number of hedge funds and other institutional investors have recently made changes to their positions in AMAG. State of Alaska Department of Revenue increased its position in shares of AMAG Pharmaceuticals by 81.3% in the second quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock worth $126,000 after buying an additional 3,081 shares during the period. Advisors Asset Management Inc. increased its position in shares of AMAG Pharmaceuticals by 259.9% in the first quarter. Advisors Asset Management Inc. now owns 6,931 shares of the specialty pharmaceutical company’s stock worth $156,000 after buying an additional 5,005 shares during the period. Mason Street Advisors LLC increased its position in shares of AMAG Pharmaceuticals by 7.4% in the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock worth $181,000 after buying an additional 554 shares during the period. Sei Investments Co. increased its position in shares of AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock worth $188,000 after buying an additional 54 shares during the period. Finally, Baird Financial Group Inc. acquired a new position in shares of AMAG Pharmaceuticals during the first quarter worth about $220,000.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.